synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-15. Anything still debated is marked as such rather than presented as settled.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | No marketing authorization in major jurisdictions |
| Scheduling example | Prescription-only supply in some countries | Handled as an unlicensed medicine where restricted |
| Sports classification | Prohibited peptide | Appears on anti-doping prohibited lists |
| Reported presentation | Lyophilized vial | Nominal content varies between vendors |
| Detection approach | Liquid chromatography–tandem mass spectrometry | Used in anti-doping and forensic testing |
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
== Structure == GFP has a beta barrel structure consisting of eleven β-strands with a pleated sheet arrangement, with an alpha helix containing the covalently bonded chromophore 4-(p-hydroxybenzylidene)imidazolidin-5-one (HBI) running through the center. Five shorter alpha helices form caps on the ends of the structure. The beta barrel structure is a nearly perfect cylinder, 42Å long and 24Å in diameter (some studies have reported a diameter of 30Å), creating what is referred to as a "β-can" formation, which is unique to the GFP-like family. HBI, the spontaneously modified form of the tripeptide Ser65–Tyr66–Gly67, is nonfluorescent in the absence of the properly folded GFP scaffold and exists mainly in the un-ionized phenol form in wtGFP. Inward-facing sidechains of the barrel induce specific cyclization reactions in Ser65–Tyr66–Gly67 that induce ionization of HBI to the phenolate form and chromophore formation. This process of post-translational modification is referred to as maturation. The hydrogen-bonding network and electron-stacking interactions with these sidechains influence the color, intensity and photostability of GFP and its numerous derivatives. The tightly packed nature of the barrel excludes solvent molecules, protecting the chromophore fluorescence from quenching by water. In addition to the auto-cyclization of the Ser65-Tyr66-Gly67, a 1,2-dehydrogenation reaction occurs at the Tyr66 residue. Besides the three residues that form the chromophore, residues such as Gln94, Arg96, His148, Thr203, and Glu222 all act as stabilizers.
== Plot == Maia Marten is a prosecutor and mother to her diabetic son Noah, living in London. On the day she is scheduled to appear in court for the trial of crime boss Tommy Boyd, she drops Noah off at school, then goes for a run. While on her run, she receives a call coming from Noah's phone from an unnamed man in Boyd's employ. The Caller informs Maia that he has kidnapped Noah and orders her to follow his instructions to ensure Noah’s safe release. He also reveals that he has hacked her phone and is tracking her, leaving her unable to call others for help. The Caller guides Maia to a dumpster, where she finds Noah's backpack containing a gun that was used by Boyd. The Caller tells Maia he has placed Noah in a diabetic coma using his insulin pump. He instructs her to run to the Excelsus Hotel, where key witness Radian Tafa is being kept under police guard, and use the gun to kill him, telling her that if she does not succeed within one hour, Noah will die. Maia begins to run, still on the phone with the Caller, who taunts her with private information he has learned from hacking her, as well as her colleague and romantic interest Ted. She attempts to steal a phone from passersby to send a text to Ted but is unable to do so. As the Caller interrogates Maia about her father's murder, allegedly committed by her abused mother, she is struck by a car and awakens several minutes later in an ambulance. Leaping out, Maia enters the London Underground to make up time, against the Caller's orders.
=== EC 1.3.8 With a flavin as acceptor === EC 1.3.8.1: short-chain acyl-CoA dehydrogenase EC 1.3.8.2: 4,4′-diapophytoene desaturase (4,4′-diapolycopene-forming) EC 1.3.8.3: (R)-benzylsuccinyl-CoA dehydrogenase EC 1.3.8.4: isovaleryl-CoA dehydrogenase EC 1.3.8.5: 2-methyl-branched-chain-enoyl-CoA reductase EC 1.3.8.6: glutaryl-CoA dehydrogenase (ETF) EC 1.3.8.7: medium-chain acyl-CoA dehydrogenase EC 1.3.8.8: long-chain acyl-CoA dehydrogenase EC 1.3.8.9: very-long-chain acyl-CoA dehydrogenase EC 1.3.8.10: cyclohex-1-ene-1-carbonyl-CoA dehydrogenase EC 1.3.8.11: cyclohexane-1-carbonyl-CoA dehydrogenase (electron-transfer flavoprotein) EC 1.3.8.12: (2S)-methylsuccinyl-CoA dehydrogenase EC 1.3.8.13: crotonobetainyl-CoA reductase EC 1.3.8.14: L-prolyl-[peptidyl-carrier protein] dehydrogenase EC 1.3.8.15: 3-(aryl)acrylate reductase EC 1.3.8.16: 2-amino-4-deoxychorismate dehydrogenase EC 1.3.8.17: dehydro coenzyme F420 reductase
== History == In 1959, physicist Richard Feynman gave a talk titled "There's Plenty of Room at the Bottom" to the American Physical Society. He imagined a world in which "we could arrange atoms one by one, just as we want them." This idea set the stage for the bottom-up synthesis approach in which constituent components interact to form higher-ordered structures in a controllable manner. The study of self-assembly of nanoparticles began with recognition that some properties of atoms and molecules enable them to arrange themselves into patterns. A variety of applications where the self-assembly of nanoparticles might be useful. For example, building sensors or computer chips. Definition Self-assembly is defined as a process in which individual units of material associate with themselves spontaneously into a defined and organized structure or larger units with minimal external direction. Self-assembly is recognized as a highly useful technique to achieve outstanding qualities in both organic and inorganic nanostructures. According to George M.
=== Transformation in the environment === The silver nanoparticles that pass through wastewater treatment plants undergo transformations in the environment through changes in aggregation state, oxidation state, precipitation of secondary phases, or sorption of organic species. These transformations can result in the formation of colloidal solutions. Each of these new species potentially have toxic effects which have yet to be fully examined. Most silver nanoparticles in products have an organic shell structure around a core of Ag0. This shell is often created with carboxylic acids functional groups, usually using citrate, leading to stabilization through adsorption or covalent attachment of organic compounds. In seawater, glutathione reacts with citrate to form a thioester via esterification.
Sources: en.wikipedia.org
"History of the Laboratory". LLNL. July 14, 2002. Archived from the original on October 12, 2006. Serving the Nation for Fifty Years: 1952–2002 Lawrence Livermore National Laboratory [LLNL], Fifty Years of Accomplishments (PDF) (Report). LLNL. 2002. UCRL-AR-148833. Archived from the original (PDF) on October 15, 2011. Retrieved August 26, 2013. LLNL Industrial Partnerships and Commercialization (IPAC) (official website)
With the merger of the laboratories into a single entity, the history offices at each site ceased to maintain independent histories and all history functions were transferred to a central History Office located at AFRL HQ at Wright-Patterson AFB. In homage to the predecessor laboratories, the new organization named four of the research sites after the laboratories and assured that each laboratory's history would be preserved as inactivated units. In 2023, the National Advanced Air Mobility Center of Excellence was completed to help the Laboratory, private companies, and local academics collaborate on the research of eVTOL and UAS aircraft.
Aldo-keto reductase family 1 (AKR1) is a family of aldo-keto reductase enzymes that is involved in steroid metabolism. It includes the AKR1C and AKR1D subgroups, which respectively consist of AKR1C1–AKR1C4 and AKR1D1. Together with short-chain dehydrogenase/reductases (SDRs), these enzymes catalyze oxidoreductions, act on the C3, C5, C11, C17 and C20 positions of steroids, and function as 3α-HSDTooltip 3α-Hydroxysteroid dehydrogenases, 3β-HSDsTooltip 3β-Hydroxysteroid dehydrogenases, 5β-reductases, 11β-HSDsTooltip 11β-Hydroxysteroid dehydrogenases, 17β-HSDsTooltip 17β-hydroxysteroid dehydrogenases, and 20α-HSDsTooltip 20α-Hydroxysteroid dehydrogenases, respectively. The AKR1C enzymes act as 3-, 17- and 20-ketosteroid reductases, while AKR1D1 acts as the sole 5β-reductase in humans. AKR1A1; AKR1B1; AKR1B10; AKR1C1; AKR1C2; AKR1C3; AKR1C4; AKR1D1; Others Steroidogenic enzyme
The isotopes 280Rg and 281Rg are promising for chemical experimentation and may be produced as the granddaughters of the moscovium isotopes 288Mc and 289Mc respectively; their parents are the nihonium isotopes 284Nh and 285Nh, which have already received preliminary chemical investigations.
The study used a combination of existing, cheap drugs ahead of usual radiotherapy treatment. 24 October California-based startup Atom Computing announces a 1,225-qubit quantum computer, the first to break the 1,000+ barrier, which it plans to release in 2024. NASA provides updated details of its Nancy Grace Roman Space Telescope, planned for launch by 2027. JT-60SA, the world's largest fusion reactor, located in Japan, achieves first plasma. A study reviewing the 'planetary vital signs' reports deeply concerning patterns and records, minimal progress of mitigation by humanity, and a set of broad policy recommendations. It represents an annual update to a 2019 study that has been signed by now 15,000 researchers to track the state of climate change and its mitigation. 25 October – Scientists, helped by information derived from the Mars InSight lander, report that the planet Mars has a radioactive magma ocean under its crust. 26 October – Astronomers report studies that suggest for the first time that the planet Venus may have had plate tectonics during ancient times, and, as a result, may have had a cooler more habitable environment, and possibly one capable of generating life forms. 28 October – Positive results are reported in a study with rats of the experimental vaccine calixcoca meant for treating cocaine addiction. Clinical trials in humans are the next step of the study.
Sources: en.wikipedia.org
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.
The peptide is listed as prohibited in competitive sport, so laboratories develop detection methods and monitor for its presence. Its appearance in enforcement reports reflects that classification rather than any approved athletic use. Analytical work in this area focuses on identifying the molecule and its breakdown products in biological samples.
Chromatographic separation combined with mass spectrometry identifies the peptide and estimates its amount in a sample. Testing can confirm whether the expected molecule is present and at what concentration. It cannot establish how a product was manufactured or whether it meets any purity standard.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.